Skip to content
RNAWiki
Checking…
All public datasets

Public dataset

Recorded source agreement and disagreement

Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.

What this does not mean: agree can mean only that sources print the same normalized reading; it is not clinical-context equivalence, independent replication, or proof. differ requires matching structured context and disjoint comparable values. not_comparable and insufficient_context are not disagreement.
Public rows
1,681
Generated
Schema version
source-consensus/2

Coverage

What this run contains

Compared medicine fields
1,681
Agree
1,282
Differ
0
Not comparable
12
Insufficient context
387
Fields represented
5
bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution

Method

How the rows were made

  1. Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
  2. One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
  3. Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
  4. not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
  5. The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
  6. Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
  7. documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.

Limits

Read these before using a row

  • Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
  • The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
  • Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
  • Only the recorded fields and source documents in this snapshot are compared.
  • A source count is the number of retained source records in the row, not a count of independent experiments.

Provenance

Source examples

abacavir · bioavailability · agree

15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
The geometric mean absolute bioavailability of the tablet was 83%.

alemtuzumab · volumeOfDistribution · not_comparable

2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)
Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).

abiraterone · halfLife · insufficient_context

31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.

Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.

Schema

Fields in the public projection

FieldTypeMeaning
medicineSlugstringStable RNAWiki medicine route key.
fieldstringRecorded pharmacokinetic field being compared.
comparisonStatestringagree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero.
comparisonReasonsstring[]Deterministic codes explaining the state.
documentsExaminednumberRecorded source documents considered for the field.
sourceCountnumberRecorded source readings represented.
agreementRatenumberShare represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability.
readingsconsensus-reading[]Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt.

Reader

Search and filter the rows

Case-insensitive text search over the public fields named for this dataset.

Exact comparability state.

Exact recorded field key.

Clear

Showing 181–190 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.

  1. Projected row 181

    Medicine slug
    birch-triterpenes
    Compared field
    proteinBinding
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    2
    Source count
    2
    Agreement rate
    1
    Recorded readings

    1. >99.9 %

      Numeric value
      99.9
      Unit
      %
      Source records
      2

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 2 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:32ba9194-734c-47d4-84e1-b21e28a85ec5 (opens source in a new tab)

        Birch Triterpenes label

        Version not recorded · Effective date not recorded

        Distribution Plasma protein binding of betulin in vitro is >99.9 %.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:da793f2d-0a3d-4792-8c22-982f9f8cdd97 (opens source in a new tab)

        Birch Triterpenes label

        Version not recorded · Effective date not recorded

        Distribution Plasma protein binding of betulin in vitro is >99.9 %.

  2. Projected row 182

    Medicine slug
    bisoprolol
    Compared field
    bioavailability
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    30
    Source count
    30
    Agreement rate
    1
    Recorded readings

    1. 80%

      Numeric value
      80
      Unit
      %
      Source records
      30

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 30 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e907bfcb-5e64-45b8-ae9d-822b3d360104 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Pharmacokinetics and Metabolism The absolute bioavailability after a 10 mg oral dose of bisoprolol fumarate is about 80%.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9b2eb4ea-001e-436c-93ba-20a7f5bc5f04 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Pharmacokinetics and Metabolism The absolute bioavailability after a 10 mg oral dose of bisoprolol fumarate is about 80%.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c8fa858c-7e42-4134-9fc6-604a11a66fe2 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Pharmacokinetics and Metabolism The absolute bioavailability after a 10 mg oral dose of bisoprolol fumarate is about 80%.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:200ab93b-6ad3-46cb-8f57-db056a14de16 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Pharmacokinetics and Metabolism The absolute bioavailability after a 10 mg oral dose of bisoprolol fumarate is about 80%.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:65da2d2e-cce8-4bf6-a12d-3565b4b6b7c8 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Pharmacokinetics and Metabolism The absolute bioavailability after a 10 mg oral dose of bisoprolol fumarate is about 80%.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4bf3278c-116f-4db7-9af0-08faaf7691a4 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Pharmacokinetics and Metabolism The absolute bioavailability after a 10 mg oral dose of bisoprolol fumarate is about 80%.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:df37d337-9978-0c31-e053-2a95a90a3258 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Pharmacokinetics and Metabolism The absolute bioavailability after a 10 mg oral dose of bisoprolol fumarate is about 80%.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3c393b41-9423-4ea6-8a79-0cbff0693471 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Pharmacokinetics and Metabolism The absolute bioavailability after a 10 mg oral dose of bisoprolol fumarate is about 80%.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:78056d0b-2265-4da3-a4fe-b96d98289848 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Pharmacokinetics and Metabolism The absolute bioavailability after a 10 mg oral dose of bisoprolol fumarate is about 80%.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:36b53e7f-e306-40a8-8d1b-d00695a4fe61 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Pharmacokinetics and Metabolism The absolute bioavailability after a 10 mg oral dose of bisoprolol fumarate is about 80%.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:084308e4-3b8b-40d6-acbf-d775772a8a73 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Pharmacokinetics and Metabolism The absolute bioavailability after a 10 mg oral dose of bisoprolol fumarate is about 80%.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4f20df45-3f9c-4a91-b394-e93a08111ec3 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Pharmacokinetics and Metabolism The absolute bioavailability after a 10 mg oral dose of bisoprolol fumarate is about 80%.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bce7e65a-148f-4ccd-9305-bc7331dbcca4 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Pharmacokinetics and Metabolism The absolute bioavailability after a 10 mg oral dose of bisoprolol fumarate is about 80%.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0ef9e45c-21ee-4e00-a9b8-280e2035b4d3 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Pharmacokinetics and Metabolism The absolute bioavailability after a 10 mg oral dose of bisoprolol fumarate is about 80%.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6ebe6ec0-6223-425c-9f3b-8ab8dd8b3f5f (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Pharmacokinetics and Metabolism The absolute bioavailability after a 10 mg oral dose of bisoprolol fumarate is about 80%.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d540ef44-9016-9d66-e053-2a95a90a16a9 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Pharmacokinetics and Metabolism The absolute bioavailability after a 10 mg oral dose of bisoprolol fumarate is about 80%.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6517d564-ea55-4084-a8ab-34fea548c24e (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Pharmacokinetics and Metabolism The absolute bioavailability after a 10 mg oral dose of bisoprolol fumarate is about 80%.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4f11e64c-732e-419a-bc29-9cd2ff86d0b9 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Pharmacokinetics and Metabolism The absolute bioavailability after a 10 mg oral dose of bisoprolol fumarate is about 80%.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:428ef54d-8828-4756-a087-a1b7b2d6b8d6 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Pharmacokinetics and Metabolism The absolute bioavailability after a 10 mg oral dose of bisoprolol fumarate is about 80%.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c0e309f3-82c3-4629-b790-fb8538b87369 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Pharmacokinetics and Metabolism The absolute bioavailability after a 10 mg oral dose of bisoprolol fumarate is about 80%.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:91d114ce-5551-455e-82df-d058eb222ac1 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Pharmacokinetics and Metabolism The absolute bioavailability after a 10 mg oral dose of bisoprolol fumarate is about 80%.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2564646d-183c-4759-8726-155a4c22aa2b (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Pharmacokinetics and Metabolism The absolute bioavailability after a 10 mg oral dose of bisoprolol fumarate is about 80%.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bba0bc2b-602f-4df1-a761-85bd3c80c7de (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Pharmacokinetics and Metabolism The absolute bioavailability after a 10 mg oral dose of bisoprolol fumarate is about 80%.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7556f457-c4d3-49d6-b383-0ade6d489091 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Pharmacokinetics and Metabolism The absolute bioavailability after a 10 mg oral dose of bisoprolol fumarate is about 80%.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6566dcbe-3e25-4828-9c10-3d041000bc77 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Pharmacokinetics and Metabolism The absolute bioavailability after a 10 mg oral dose of bisoprolol fumarate is about 80%.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c3ee566c-74c4-45f4-a947-526a7313e326 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Pharmacokinetics and Metabolism The absolute bioavailability after a 10 mg oral dose of bisoprolol fumarate is about 80%.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:83e4b4e5-9130-44c8-abab-fcd0db5d8c49 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Pharmacokinetics and Metabolism The absolute bioavailability after a 10 mg oral dose of bisoprolol fumarate is about 80%.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ae10b8e1-557d-4437-8a1d-89d7844122c8 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Pharmacokinetics and Metabolism The absolute bioavailability after a 10 mg oral dose of bisoprolol fumarate is about 80%.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f6ce8f14-43fc-4c5e-8378-62ca7121e918 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Pharmacokinetics and Metabolism The absolute bioavailability after a 10 mg oral dose of bisoprolol fumarate is about 80%.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7ec24259-0f37-4389-873b-e62267a21d67 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Pharmacokinetics and Metabolism The absolute bioavailability after a 10 mg oral dose of bisoprolol fumarate is about 80%.

  3. Projected row 183

    Medicine slug
    bisoprolol
    Compared field
    halfLife
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    30
    Source count
    30
    Agreement rate
    0.966667
    Recorded readings

    1. 9-12 hours

      Numeric value
      9
      Unit
      hours
      Source records
      29

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 29 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e907bfcb-5e64-45b8-ae9d-822b3d360104 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        The plasma elimination half-life is 9-12 hours and is slightly longer in elderly patients, in part because of decreased renal function in that population.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9b2eb4ea-001e-436c-93ba-20a7f5bc5f04 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        The plasma elimination half-life is 9-12 hours and is slightly longer in elderly patients, in part because of decreased renal function in that population.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c8fa858c-7e42-4134-9fc6-604a11a66fe2 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        The plasma elimination half-life is 9-12 hours and is slightly longer in elderly patients, in part because of decreased renal function in that population.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:200ab93b-6ad3-46cb-8f57-db056a14de16 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        The plasma elimination half-life is 9-12 hours and is slightly longer in elderly patients, in part because of decreased renal function in that population.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:65da2d2e-cce8-4bf6-a12d-3565b4b6b7c8 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        The plasma elimination half-life is 9-12 hours and is slightly longer in elderly patients, in part because of decreased renal function in that population.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4bf3278c-116f-4db7-9af0-08faaf7691a4 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        The plasma elimination half-life is 9 to 12 hours and is slightly longer in elderly patients, in part because of decreased renal function in that population.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:df37d337-9978-0c31-e053-2a95a90a3258 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        The plasma elimination half-life is 9-12 hours and is slightly longer in elderly patients, in part because of decreased renal function in that population.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:78056d0b-2265-4da3-a4fe-b96d98289848 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        The plasma elimination half-life is 9 to 12 hours and is slightly longer in elderly patients, in part because of decreased renal function in that population.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:36b53e7f-e306-40a8-8d1b-d00695a4fe61 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        The plasma elimination half-life is 9-12 hours and is slightly longer in elderly patients, in part because of decreased renal function in that population.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:084308e4-3b8b-40d6-acbf-d775772a8a73 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        The plasma elimination half-life is 9-12 hours and is slightly longer in elderly patients, in part because of decreased renal function in that population.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4f20df45-3f9c-4a91-b394-e93a08111ec3 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        The plasma elimination half-life is 9-12 hours and is slightly longer in elderly patients, in part because of decreased renal function in that population.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bce7e65a-148f-4ccd-9305-bc7331dbcca4 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        The plasma elimination half-life is 9-12 hours and is slightly longer in elderly patients, in part because of decreased renal function in that population.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0ef9e45c-21ee-4e00-a9b8-280e2035b4d3 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        The plasma elimination half-life is 9-12 hours and is slightly longer in elderly patients, in part because of decreased renal function in that population.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6ebe6ec0-6223-425c-9f3b-8ab8dd8b3f5f (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        The plasma elimination half-life is 9-12 hours and is slightly longer in elderly patients, in part because of decreased renal function in that population.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d540ef44-9016-9d66-e053-2a95a90a16a9 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        The plasma elimination half-life is 9 to 12 hours and is slightly longer in elderly patients, in part because of decreased renal function in that population.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6517d564-ea55-4084-a8ab-34fea548c24e (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        The plasma elimination half-life is 9-12 hours and is slightly longer in elderly patients, in part because of decreased renal function in that population.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4f11e64c-732e-419a-bc29-9cd2ff86d0b9 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        The plasma elimination half-life is 9-12 hours and is slightly longer in elderly patients, in part because of decreased renal function in that population.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:428ef54d-8828-4756-a087-a1b7b2d6b8d6 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        The plasma elimination half-life is 9-12 hours and is slightly longer in elderly patients, in part because of decreased renal function in that population.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c0e309f3-82c3-4629-b790-fb8538b87369 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        The plasma elimination half-life is 9-12 hours and is slightly longer in elderly patients, in part because of decreased renal function in that population.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:91d114ce-5551-455e-82df-d058eb222ac1 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        The plasma elimination half-life is 9 to 12 hours and is slightly longer in elderly patients, in part because of decreased renal function in that population.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2564646d-183c-4759-8726-155a4c22aa2b (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        The plasma elimination half-life is 9 to 12 hours and is slightly longer in elderly patients, in part because of decreased renal function in that population.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bba0bc2b-602f-4df1-a761-85bd3c80c7de (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        The plasma elimination half-life is 9 to 12 hours and is slightly longer in elderly patients, in part because of decreased renal function in that population.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7556f457-c4d3-49d6-b383-0ade6d489091 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        The plasma elimination half-life is 9-12 hours and is slightly longer in elderly patients, in part because of decreased renal function in that population.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6566dcbe-3e25-4828-9c10-3d041000bc77 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        The plasma elimination half-life is 9-12 hours and is slightly longer in elderly patients, in part because of decreased renal function in that population.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c3ee566c-74c4-45f4-a947-526a7313e326 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        The plasma elimination half-life is 9 to 12 hours and is slightly longer in elderly patients, in part because of decreased renal function in that population.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:83e4b4e5-9130-44c8-abab-fcd0db5d8c49 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        The plasma elimination half-life is 9-12 hours and is slightly longer in elderly patients, in part because of decreased renal function in that population.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ae10b8e1-557d-4437-8a1d-89d7844122c8 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        The plasma elimination half-life is 9-12 hours and is slightly longer in elderly patients, in part because of decreased renal function in that population.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f6ce8f14-43fc-4c5e-8378-62ca7121e918 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        The plasma elimination half-life is 9-12 hours and is slightly longer in elderly patients, in part because of decreased renal function in that population.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7ec24259-0f37-4389-873b-e62267a21d67 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        The plasma elimination half-life is 9 to 12 hours and is slightly longer in elderly patients, in part because of decreased renal function in that population.

    2. 9 hours

      Numeric value
      9
      Unit
      hours
      Source records
      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3c393b41-9423-4ea6-8a79-0cbff0693471 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        The plasma elimination half-life is 9 hours to 12 hours and is slightly longer in elderly patients, in part because of decreased renal function in that population.

  4. Projected row 184

    Medicine slug
    bisoprolol
    Compared field
    tMax
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    30
    Source count
    30
    Agreement rate
    0.966667
    Recorded readings

    1. 2-4 hours

      Numeric value
      2
      Unit
      hours
      Source records
      29

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 29 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e907bfcb-5e64-45b8-ae9d-822b3d360104 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations occur within 2-4 hours of dosing with 5 to 20 mg, and mean peak values range from 16 ng/mL at 5 mg to 70 ng/mL at 20 mg.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9b2eb4ea-001e-436c-93ba-20a7f5bc5f04 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations occur within 2-4 hours of dosing with 5 to 20 mg, and mean peak values range from 16 ng/mL at 5 mg to 70 ng/mL at 20 mg.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c8fa858c-7e42-4134-9fc6-604a11a66fe2 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations occur within 2-4 hours of dosing with 5 to 20 mg, and mean peak values range from 16 ng/mL at 5 mg to 70 ng/mL at 20 mg.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:200ab93b-6ad3-46cb-8f57-db056a14de16 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations occur within 2-4 hours of dosing with 5 to 20 mg, and mean peak values range from 16 ng/mL at 5 mg to 70 ng/mL at 20 mg.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:65da2d2e-cce8-4bf6-a12d-3565b4b6b7c8 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations occur within 2-4 hours of dosing with 5 to 20 mg, and mean peak values range from 16 ng/mL at 5 mg to 70 ng/mL at 20 mg.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4bf3278c-116f-4db7-9af0-08faaf7691a4 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations occur within 2 to 4 hours of dosing with 5 to 20 mg, and mean peak values range from 16 ng/mL at 5 mg to 70 ng/mL at 20 mg.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:df37d337-9978-0c31-e053-2a95a90a3258 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations occur within 2-4 hours of dosing with 5 to 20 mg, and mean peak values range from 16 ng/mL at 5 mg to 70 ng/mL at 20 mg.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:78056d0b-2265-4da3-a4fe-b96d98289848 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations occur within 2 to 4 hours of dosing with 5 mg to 20 mg, and mean peak values range from 16 ng/mL at 5 mg to 70 ng/mL at 20 mg.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:36b53e7f-e306-40a8-8d1b-d00695a4fe61 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations occur within 2-4 hours of dosing with 5 to 20 mg, and mean peak values range from 16 ng/mL at 5 mg to 70 ng/mL at 20 mg.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:084308e4-3b8b-40d6-acbf-d775772a8a73 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations occur within 2-4 hours of dosing with 5 to 20 mg, and mean peak values range from 16 ng/mL at 5 mg to 70 ng/mL at 20 mg.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4f20df45-3f9c-4a91-b394-e93a08111ec3 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations occur within 2-4 hours of dosing with 5 to 20 mg, and mean peak values range from 16 ng/mL at 5 mg to 70 ng/mL at 20 mg.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bce7e65a-148f-4ccd-9305-bc7331dbcca4 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations occur within 2-4 hours of dosing with 5 to 20 mg, and mean peak values range from 16 ng/mL at 5 mg to 70 ng/mL at 20 mg.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0ef9e45c-21ee-4e00-a9b8-280e2035b4d3 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations occur within 2-4 hours of dosing with 5 to 20 mg, and mean peak values range from 16 ng/mL at 5 mg to 70 ng/mL at 20 mg.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6ebe6ec0-6223-425c-9f3b-8ab8dd8b3f5f (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations occur within 2-4 hours of dosing with 5 to 20 mg, and mean peak values range from 16 ng/mL at 5 mg to 70 ng/mL at 20 mg.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d540ef44-9016-9d66-e053-2a95a90a16a9 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations occur within 2 to 4 hours of dosing with 5 to 20 mg, and mean peak values range from 16 ng/mL at 5 mg to 70 ng/mL at 20 mg.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6517d564-ea55-4084-a8ab-34fea548c24e (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations occur within 2-4 hours of dosing with 5 to 20 mg, and mean peak values range from 16 ng/mL at 5 mg to 70 ng/mL at 20 mg.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4f11e64c-732e-419a-bc29-9cd2ff86d0b9 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations occur within 2-4 hours of dosing with 5 to 20 mg, and mean peak values range from 16 ng/mL at 5 mg to 70 ng/mL at 20 mg.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:428ef54d-8828-4756-a087-a1b7b2d6b8d6 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations occur within 2-4 hours of dosing with 5 to 20 mg, and mean peak values range from 16 ng/mL at 5 mg to 70 ng/mL at 20 mg.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c0e309f3-82c3-4629-b790-fb8538b87369 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations occur within 2-4 hours of dosing with 5 to 20 mg, and mean peak values range from 16 ng/mL at 5 mg to 70 ng/mL at 20 mg.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:91d114ce-5551-455e-82df-d058eb222ac1 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations occur within 2 to 4 hours of dosing with 5 mg to 20 mg, and mean peak values range from 16 ng/mL at 5 mg to 70 ng/mL at 20 mg.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2564646d-183c-4759-8726-155a4c22aa2b (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations occur within 2 to 4 hours of dosing with 5 to 20 mg, and mean peak values range from 16 ng/mL at 5 mg to 70 ng/mL at 20 mg.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bba0bc2b-602f-4df1-a761-85bd3c80c7de (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations occur within 2 to 4 hours of dosing with 5 mg to 20 mg, and mean peak values range from 16 ng/mL at 5 mg to 70 ng/mL at 20 mg.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7556f457-c4d3-49d6-b383-0ade6d489091 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations occur within 2-4 hours of dosing with 5 to 20 mg, and mean peak values range from 16 ng/mL at 5 mg to 70 ng/mL at 20 mg.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6566dcbe-3e25-4828-9c10-3d041000bc77 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations occur within 2-4 hours of dosing with 5 to 20 mg, and mean peak values range from 16 ng/mL at 5 mg to 70 ng/mL at 20 mg.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c3ee566c-74c4-45f4-a947-526a7313e326 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations occur within 2 to 4 hours of dosing with 5 to 20 mg, and mean peak values range from 16 ng/mL at 5 mg to 70 ng/mL at 20 mg.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:83e4b4e5-9130-44c8-abab-fcd0db5d8c49 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations occur within 2-4 hours of dosing with 5 to 20 mg, and mean peak values range from 16 ng/mL at 5 mg to 70 ng/mL at 20 mg.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ae10b8e1-557d-4437-8a1d-89d7844122c8 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations occur within 2-4 hours of dosing with 5 to 20 mg, and mean peak values range from 16 ng/mL at 5 mg to 70 ng/mL at 20 mg.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f6ce8f14-43fc-4c5e-8378-62ca7121e918 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations occur within 2-4 hours of dosing with 5 to 20 mg, and mean peak values range from 16 ng/mL at 5 mg to 70 ng/mL at 20 mg.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7ec24259-0f37-4389-873b-e62267a21d67 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations occur within 2 to 4 hours of dosing with 5 mg to 20 mg, and mean peak values range from 16 ng/mL at 5 mg to 70 ng/mL at 20 mg.

    2. 2 hours

      Numeric value
      2
      Unit
      hours
      Source records
      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3c393b41-9423-4ea6-8a79-0cbff0693471 (opens source in a new tab)

        Bisoprolol label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations occur within 2 hours to 4 hours of dosing with 5 mg to 20 mg and mean peak values range from 16 ng/mL at 5 mg to 70 ng/mL at 20 mg.

  5. Projected row 185

    Medicine slug
    bivalirudin
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    15
    Source count
    15
    Agreement rate
    1
    Recorded readings

    1. 3.5 hours

      Numeric value
      3.5
      Unit
      hours
      Source records
      15

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 15 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:26fb46f6-0088-42b8-b6f2-c67224776803 (opens source in a new tab)

        Bivalirudin label

        Version not recorded · Effective date not recorded

        In dialysis patients, clearance was reduced by 70%, with a half-life of 3.5 hours.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:42aa2630-83d6-433d-8277-0f672cf8d71d (opens source in a new tab)

        Bivalirudin label

        Version not recorded · Effective date not recorded

        In dialysis patients, clearance was reduced by 70%, with a half-life of 3.5 hours.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c727199d-f4cd-4658-8fdf-568590beface (opens source in a new tab)

        Bivalirudin label

        Version not recorded · Effective date not recorded

        In dialysis patients, clearance was reduced by 70%, with a half-life of 3.5 hours.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:95d150e7-f152-4091-b831-e469c9578a54 (opens source in a new tab)

        Bivalirudin label

        Version not recorded · Effective date not recorded

        In dialysis patients, clearance was reduced by 70%, with a half-life of 3.5 hours.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c20969cb-72d4-469b-9bd8-332250d896c3 (opens source in a new tab)

        Bivalirudin label

        Version not recorded · Effective date not recorded

        In dialysis patients, clearance was reduced by 70%, with a half-life of 3.5 hours.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:19a4afc5-151d-4d3c-bfef-48aa8797d695 (opens source in a new tab)

        Bivalirudin label

        Version not recorded · Effective date not recorded

        In dialysis patients, clearance was reduced by 70%, with a half-life of 3.5 hours.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:91cf9d00-29e0-4357-a184-f70026c47edb (opens source in a new tab)

        Bivalirudin label

        Version not recorded · Effective date not recorded

        In dialysis patients, clearance was reduced by 70%, with a half-life of 3.5 hours.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4119b710-ef30-4e3e-b99a-38e42b4b3fca (opens source in a new tab)

        Bivalirudin label

        Version not recorded · Effective date not recorded

        In dialysis patients, clearance was reduced by 70%, with a half-life of 3.5 hours.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:19beb2ae-6064-3c24-fe50-0cee86896979 (opens source in a new tab)

        Bivalirudin label

        Version not recorded · Effective date not recorded

        In dialysis patients, clearance was reduced by 70%, with a half-life of 3.5 hours.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ce56f806-7845-429d-a1ce-c2dbf79b22eb (opens source in a new tab)

        Bivalirudin label

        Version not recorded · Effective date not recorded

        In dialysis patients, clearance was reduced by 70%, with a half-life of 3.5 hours.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5d9a45c6-e234-4d56-9132-5e24e65852e6 (opens source in a new tab)

        Bivalirudin label

        Version not recorded · Effective date not recorded

        In dialysis patients, clearance was reduced by 70%, with a half-life of 3.5 hours.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:61de12ff-e280-4bab-9804-43869ec45fa7 (opens source in a new tab)

        Bivalirudin label

        Version not recorded · Effective date not recorded

        In dialysis patients, clearance was reduced by 70%, with a half-life of 3.5 hours.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:af943fa0-ab0f-4b62-9ff0-54ee24cdb772 (opens source in a new tab)

        Bivalirudin label

        Version not recorded · Effective date not recorded

        In dialysis patients, clearance was reduced by 70%, with a half-life of 3.5 hours.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:50975be1-6d1f-497c-b989-1825a0fae1a7 (opens source in a new tab)

        Bivalirudin label

        Version not recorded · Effective date not recorded

        In dialysis patients, clearance was reduced by 70%, with a half-life of 3.5 hours.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e574d04f-67b4-4a84-9d66-8c2d54f95120 (opens source in a new tab)

        Bivalirudin label

        Version not recorded · Effective date not recorded

        In dialysis patients, clearance was reduced by 70%, with a half-life of 3.5 hours.

  6. Projected row 186

    Medicine slug
    bleomycin
    Compared field
    bioavailability
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    6
    Source count
    6
    Agreement rate
    1
    Recorded readings

    1. 100%

      Numeric value
      100
      Unit
      %
      Source records
      6

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 6 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e629ba5a-4e08-4249-9551-af6dbd98a7e4 (opens source in a new tab)

        Bleomycin label

        Version not recorded · Effective date not recorded

        Systemic bioavailability of bleomycin is 100% and 70% following intramuscular and subcutaneous administrations, respectively, and 45% following both intraperitoneal and intrapleural administrations, compared to intravenous and bolus administration.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:905e0984-2ce3-481c-b1a0-0ef0a616479a (opens source in a new tab)

        Bleomycin label

        Version not recorded · Effective date not recorded

        Systemic bioavailability of bleomycin is 100% and 70% following intramuscular and subcutaneous administrations, respectively, and 45% following both intraperitoneal and intrapleural administrations, compared to intravenous and bolus administration.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:640602f9-a7df-46f0-a9b1-19c471008bee (opens source in a new tab)

        Bleomycin label

        Version not recorded · Effective date not recorded

        Systemic bioavailability of bleomycin is 100% and 70% following intramuscular and subcutaneous administrations, respectively, and 45% following both intraperitoneal and intrapleural administrations, compared to intravenous and bolus administration.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cccfb763-79fa-4186-89fb-d8d061d3c161 (opens source in a new tab)

        Bleomycin label

        Version not recorded · Effective date not recorded

        Systemic bioavailability of bleomycin is 100% and 70% following intramuscular and subcutaneous administrations, respectively, and 45% following both intraperitoneal and intrapleural administrations, compared to intravenous and bolus administration.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b5806c40-12ce-48e3-8abd-9f8997ef4428 (opens source in a new tab)

        Bleomycin label

        Version not recorded · Effective date not recorded

        Systemic bioavailability of bleomycin is 100% and 70% following intramuscular and subcutaneous administrations, respectively, and 45% following both intraperitoneal and intrapleural administrations, compared to intravenous and bolus administration.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6824b1e1-e5fa-4371-ade9-1346e12ab0c7 (opens source in a new tab)

        Bleomycin label

        Version not recorded · Effective date not recorded

        Systemic bioavailability of bleomycin is 100% and 70% following intramuscular and subcutaneous administrations, respectively, and 45% following both intraperitoneal and intrapleural administrations, compared to intravenous and bolus administration.

  7. Projected row 187

    Medicine slug
    bleomycin
    Compared field
    halfLife
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    6
    Source count
    6
    Agreement rate
    0.833333
    Recorded readings

    1. 2 hours

      Numeric value
      2
      Unit
      hours
      Source records
      5

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 5 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:905e0984-2ce3-481c-b1a0-0ef0a616479a (opens source in a new tab)

        Bleomycin label

        Version not recorded · Effective date not recorded

        In patients with normal renal function, plasma concentrations of bleomycin decline biexponentially with a mean terminal half-life of 2 hours following intravenous bolus administration.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:640602f9-a7df-46f0-a9b1-19c471008bee (opens source in a new tab)

        Bleomycin label

        Version not recorded · Effective date not recorded

        In patients with normal renal function, plasma concentrations of bleomycin decline biexponentially with a mean terminal half-life of 2 hours following intravenous bolus administration.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cccfb763-79fa-4186-89fb-d8d061d3c161 (opens source in a new tab)

        Bleomycin label

        Version not recorded · Effective date not recorded

        In patients with normal renal function, plasma concentrations of bleomycin decline biexponentially with a mean terminal half-life of 2 hours following intravenous bolus administration.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b5806c40-12ce-48e3-8abd-9f8997ef4428 (opens source in a new tab)

        Bleomycin label

        Version not recorded · Effective date not recorded

        In patients with normal renal function, plasma concentrations of bleomycin decline biexponentially with a mean terminal half-life of 2 hours following intravenous bolus administration.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6824b1e1-e5fa-4371-ade9-1346e12ab0c7 (opens source in a new tab)

        Bleomycin label

        Version not recorded · Effective date not recorded

        In patients with normal renal function, plasma concentrations of bleomycin decline biexponentially with a mean terminal half-life of 2 hours following intravenous bolus administration.

    2. 4.4 to 6.0 hours

      Numeric value
      4.4
      Unit
      hours
      Source records
      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e629ba5a-4e08-4249-9551-af6dbd98a7e4 (opens source in a new tab)

        Bleomycin label

        Version not recorded · Effective date not recorded

        Terminal half-life of bleomycin also increased from 4.4 to 6.0 hours.

  8. Projected row 188

    Medicine slug
    bleomycin
    Compared field
    volumeOfDistribution
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    6
    Source count
    6
    Agreement rate
    1
    Recorded readings

    1. 17.5 L

      Numeric value
      17.5
      Unit
      L
      Source records
      6

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 6 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e629ba5a-4e08-4249-9551-af6dbd98a7e4 (opens source in a new tab)

        Bleomycin label

        Version not recorded · Effective date not recorded

        Distribution Bleomycin is widely distributed throughout the body with a mean volume of distribution of 17.5 L/m 2 in patients following a 15 units/m 2 intravenous bolus dose.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:905e0984-2ce3-481c-b1a0-0ef0a616479a (opens source in a new tab)

        Bleomycin label

        Version not recorded · Effective date not recorded

        Distribution Bleomycin is widely distributed throughout the body with a mean volume of distribution of 17.5 L/m 2 in patients following a 15 units/m 2 intravenous bolus dose.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:640602f9-a7df-46f0-a9b1-19c471008bee (opens source in a new tab)

        Bleomycin label

        Version not recorded · Effective date not recorded

        Distribution Bleomycin is widely distributed throughout the body with a mean volume of distribution of 17.5 L/m 2 in patients following a 15 units/m 2 intravenous bolus dose.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cccfb763-79fa-4186-89fb-d8d061d3c161 (opens source in a new tab)

        Bleomycin label

        Version not recorded · Effective date not recorded

        Distribution Bleomycin is widely distributed throughout the body with a mean volume of distribution of 17.5 L/m 2 in patients following a 15 units/m 2 IV bolus dose.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b5806c40-12ce-48e3-8abd-9f8997ef4428 (opens source in a new tab)

        Bleomycin label

        Version not recorded · Effective date not recorded

        Distribution Bleomycin is widely distributed throughout the body with a mean volume of distribution of 17.5 L/m 2 in patients following a 15 units/m 2 intravenous bolus dose.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6824b1e1-e5fa-4371-ade9-1346e12ab0c7 (opens source in a new tab)

        Bleomycin label

        Version not recorded · Effective date not recorded

        Distribution Bleomycin is widely distributed throughout the body with a mean volume of distribution of 17.5 L/m 2 in patients following a 15 units/m 2 intravenous bolus dose.

  9. Projected row 189

    Medicine slug
    bortezomib
    Compared field
    halfLife
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    29
    Source count
    29
    Agreement rate
    0.931034
    Recorded readings

    1. 40 to 193 hours

      Numeric value
      40
      Unit
      hours
      Source records
      27

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 27 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:854be921-5fd9-482a-8432-a0c0241625f8 (opens source in a new tab)

        Bortezomib label

        Version not recorded · Effective date not recorded

        Elimination The mean elimination half-life of bortezomib upon multiple dosing ranged from 40 to 193 hours after the 1 mg/m 2 dose and 76 to 108 hours after the 1.3 mg/m 2 dose.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:04aafa6a-a50d-4a47-a831-be8e8bb992ac (opens source in a new tab)

        Bortezomib label

        Version not recorded · Effective date not recorded

        Elimination The mean elimination half-life of bortezomib upon multiple dosing ranged from 40 to 193 hours after the 1 mg/m 2 dose and 76 to 108 hours after the 1.3 mg/m 2 dose.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0eb8daef-18da-43bb-b7c6-38c4c8b5dd80 (opens source in a new tab)

        Bortezomib label

        Version not recorded · Effective date not recorded

        Elimination The mean elimination half-life of bortezomib upon multiple dosing ranged from 40 to 193 hours after the 1 mg/m 2 dose and 76 to 108 hours after the 1.3 mg/m 2 dose.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b17ca681-59a5-4af7-98a4-953b38379893 (opens source in a new tab)

        Bortezomib label

        Version not recorded · Effective date not recorded

        Elimination The mean elimination half-life of bortezomib upon multiple dosing ranged from 40 to 193 hours after the 1 mg/m 2 dose and 76 to 108 hours after the 1.3 mg/m 2 dose.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b92628dd-fa09-4c3a-b6a3-66426025807c (opens source in a new tab)

        Bortezomib label

        Version not recorded · Effective date not recorded

        Elimination The mean elimination half-life of bortezomib upon multiple dosing ranged from 40 to 193 hours after the 1 mg/m 2 dose and 76 to 108 hours after the 1.3 mg/m 2 dose.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3494c357-a692-4e55-89e1-93532b0baef7 (opens source in a new tab)

        Bortezomib label

        Version not recorded · Effective date not recorded

        Elimination The mean elimination half-life of bortezomib upon multiple dosing ranged from 40 to 193 hours after the 1 mg/m 2 dose and 76 to 108 hours after the 1.3 mg/m 2 dose.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3f02670b-5683-780c-9d38-5d8f0ef43a14 (opens source in a new tab)

        Bortezomib label

        Version not recorded · Effective date not recorded

        Elimination The mean elimination half-life of bortezomib upon multiple dosing ranged from 40 to 193 hours after the 1 mg/m 2 dose and 76 to 108 hours after the 1.3 mg/m 2 dose.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c40e6a28-d577-43d4-bca6-bef28da1d580 (opens source in a new tab)

        Bortezomib label

        Version not recorded · Effective date not recorded

        Elimination The mean elimination half-life of bortezomib upon multiple dosing ranged from 40 to 193 hours after the 1 mg/m 2 dose and 76 to 108 hours after the 1.3 mg/m 2 dose.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c6b620c6-f3d6-4ff3-b46a-50a66e6d41dd (opens source in a new tab)

        Bortezomib label

        Version not recorded · Effective date not recorded

        Elimination The mean elimination half-life of bortezomib upon multiple dosing ranged from 40 to 193 hours after the 1 mg/m 2 dose and 76 to 108 hours after the 1.3 mg/m 2 dose.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dc737d3d-2a4e-448a-ad70-e013065c411c (opens source in a new tab)

        Bortezomib label

        Version not recorded · Effective date not recorded

        Elimination The mean elimination half-life of bortezomib upon multiple dosing ranged from 40 to 193 hours after the 1 mg/m 2 dose and 76 to 108 hours after the 1.3 mg/m 2 dose.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:61539d49-dc21-4576-8813-4bc8abf3868c (opens source in a new tab)

        Bortezomib label

        Version not recorded · Effective date not recorded

        Elimination The mean elimination half-life of bortezomib upon multiple dosing ranged from 40 to 193 hours after the 1 mg/m 2 dose and 76 to 108 hours after the 1.3 mg/m 2 dose.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:322e315f-dd94-475f-94f4-4d86a7eb5590 (opens source in a new tab)

        Bortezomib label

        Version not recorded · Effective date not recorded

        Elimination The mean elimination half-life of bortezomib upon multiple dosing ranged from 40 to 193 hours after the 1 mg/m 2 dose and 76 to 108 hours after the 1.3 mg/m 2 dose.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:664bee24-7af2-2099-ac99-5dd71a1e5a14 (opens source in a new tab)

        Bortezomib label

        Version not recorded · Effective date not recorded

        Elimination The mean elimination half-life of bortezomib upon multiple dosing ranged from 40 to 193 hours after the 1 mg/m 2 dose and 76 to 108 hours after the 1.3 mg/m 2 dose.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:191d231a-1fbd-4a65-9d33-d5dc03bac381 (opens source in a new tab)

        Bortezomib label

        Version not recorded · Effective date not recorded

        Elimination The mean elimination half-life of bortezomib upon multiple dosing ranged from 40 to 193 hours after the 1 mg/m2 dose and 76 to 108 hours after the 1.3 mg/m 2 dose.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d41340c2-7fe8-42b2-aaa5-c9f9b0e9b50e (opens source in a new tab)

        Bortezomib label

        Version not recorded · Effective date not recorded

        Elimination The mean elimination half-life of bortezomib upon multiple dosing ranged from 40 to 193 hours after the 1 mg/m 2 dose and 76 to 108 hours after the 1.3 mg/m 2 dose.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:945fbaf0-7a79-4676-aa90-e9a213c0654f (opens source in a new tab)

        Bortezomib label

        Version not recorded · Effective date not recorded

        Elimination The mean elimination half-life of bortezomib upon multiple dosing ranged from 40 to 193 hours after the 1 mg/m 2 dose and 76 to 108 hours after the 1.3 mg/m 2 dose.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1521d321-e724-4ffc-adad-34bf4f44fac7 (opens source in a new tab)

        Bortezomib label

        Version not recorded · Effective date not recorded

        Elimination The mean elimination half-life of bortezomib upon multiple dosing ranged from 40 to 193 hours after the 1 mg/m 2 dose and 76 to 108 hours after the 1.3 mg/m 2 dose.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ed526447-a4fe-403b-8f08-21ce1b2fa8b7 (opens source in a new tab)

        Bortezomib label

        Version not recorded · Effective date not recorded

        Elimination The mean elimination half-life of bortezomib upon multiple dosing ranged from 40 to 193 hours after the 1 mg/m 2 dose and 76 to 108 hours after the 1.3 mg/m 2 dose.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:12500f21-8e2f-4bcd-861e-4dfca843da2e (opens source in a new tab)

        Bortezomib label

        Version not recorded · Effective date not recorded

        Elimination The mean elimination half-life of bortezomib upon multiple dosing ranged from 40 to 193 hours after the 1 mg/m 2 dose and 76 to 108 hours after the 1.3 mg/m 2 dose.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:aef02171-bf8a-43ad-b40c-7642623f9802 (opens source in a new tab)

        Bortezomib label

        Version not recorded · Effective date not recorded

        Elimination The mean elimination half-life of bortezomib upon multiple dosing ranged from 40 to 193 hours after the 1 mg/m 2 dose and 76 to 108 hours after the 1.3 mg/m 2 dose.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:41e3de39-8278-4a75-badf-601e4602080d (opens source in a new tab)

        Bortezomib label

        Version not recorded · Effective date not recorded

        Elimination The mean elimination half-life of bortezomib upon multiple dosing ranged from 40 to 193 hours after the 1 mg/m 2 dose and 76 to 108 hours after the 1.3 mg/m 2 dose.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:76c7c3a5-fd2f-403f-85fd-65a64538eee7 (opens source in a new tab)

        Bortezomib label

        Version not recorded · Effective date not recorded

        Elimination The mean elimination half-life of bortezomib upon multiple dosing ranged from 40 to 193 hours after the 1 mg/m 2 dose and 76 to 108 hours after the 1.3 mg/m 2 dose.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:decb5d94-2ea2-48d8-b08b-3196b24c0ed3 (opens source in a new tab)

        Bortezomib label

        Version not recorded · Effective date not recorded

        Elimination The mean elimination half-life of bortezomib upon multiple dosing ranged from 40 to 193 hours after the 1 mg/m 2 dose and 76 to 108 hours after the 1.3 mg/m 2 dose.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a73d7ea7-d068-4d25-b368-fc3db1898be2 (opens source in a new tab)

        Bortezomib label

        Version not recorded · Effective date not recorded

        Elimination The mean elimination half-life of bortezomib upon multiple dosing ranged from 40 to 193 hours after the 1 mg/m 2 dose and 76 to 108 hours after the 1.3 mg/m 2 dose.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b605b541-4bfd-db3e-9710-11c27f6dee6c (opens source in a new tab)

        Bortezomib label

        Version not recorded · Effective date not recorded

        Elimination The mean elimination half-life of bortezomib upon multiple dosing ranged from 40 to 193 hours after the 1 mg/m 2 dose and 76 to 108 hours after the 1.3 mg/m 2 dose.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:10f60367-0476-4acd-861b-90c18d4b8164 (opens source in a new tab)

        Bortezomib label

        Version not recorded · Effective date not recorded

        Elimination The mean elimination half-life of bortezomib upon multiple dosing ranged from 40 to 193 hours after the 1 mg/m 2 dose and 76 to 108 hours after the 1.3 mg/m 2 dose.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d79a71ec-b46d-4961-ad05-8980915cba94 (opens source in a new tab)

        Bortezomib label

        Version not recorded · Effective date not recorded

        Elimination The mean elimination half-life of bortezomib upon multiple dosing ranged from 40 to 193 hours after the 1 mg/m 2 dose and 76 to 108 hours after the 1.3 mg/m 2 dose.

    2. 40 hours

      Numeric value
      40
      Unit
      hours
      Source records
      2

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 2 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9fdf6169-699f-40eb-bda1-760253062b3c (opens source in a new tab)

        Bortezomib label

        Version not recorded · Effective date not recorded

        Elimination The mean elimination half-life of bortezomib upon multiple dosing ranged from 40 hours to 193 hours after the 1 mg/m 2 dose and 76 hours to 108 hours after the 1.3 mg/m 2 dose.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cd698074-da21-4b53-8f6b-241535a8d598 (opens source in a new tab)

        Bortezomib label

        Version not recorded · Effective date not recorded

        Elimination The mean elimination half-life of bortezomib upon multiple dosing ranged from 40 hours to 193 hours after the 1 mg/m 2 dose and 76 hours to 108 hours after the 1.3 mg/m 2 dose.

  10. Projected row 190

    Medicine slug
    bosentan
    Compared field
    bioavailability
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    6
    Source count
    6
    Agreement rate
    1
    Recorded readings

    1. 50%

      Numeric value
      50
      Unit
      %
      Source records
      6

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 6 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:749e42fb-2fe0-45dd-9268-b43bb3f4081c (opens source in a new tab)

        Bosentan label

        Version not recorded · Effective date not recorded

        Absorption The absolute bioavailability of bosentan in normal volunteers is about 50% and is unaffected by food.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:540b6f6a-79f3-4681-8c2a-268cf7cecbc9 (opens source in a new tab)

        Bosentan label

        Version not recorded · Effective date not recorded

        Absorption The absolute bioavailability of bosentan in normal volunteers is about 50% and is unaffected by food.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8444da17-6c31-492b-8842-93740f083d9d (opens source in a new tab)

        Bosentan label

        Version not recorded · Effective date not recorded

        Absorption The absolute bioavailability of bosentan in normal volunteers is about 50% and is unaffected by food.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c006d8ef-8cb7-4fb3-88eb-b2debc302a20 (opens source in a new tab)

        Bosentan label

        Version not recorded · Effective date not recorded

        Absorption The absolute bioavailability of bosentan in normal volunteers is about 50% and is unaffected by food.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c1e75179-cbea-4535-8709-f6d79c1d4004 (opens source in a new tab)

        Bosentan label

        Version not recorded · Effective date not recorded

        Absorption The absolute bioavailability of bosentan in normal volunteers is about 50% and is unaffected by food.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:39b2a85f-4322-42d4-b420-1b1d52569143 (opens source in a new tab)

        Bosentan label

        Version not recorded · Effective date not recorded

        Absorption The absolute bioavailability of bosentan in normal volunteers is about 50% and is unaffected by food.

Access

Query or download the projection

View this filtered page as JSONDownload up to 200 filtered CSV rows
GET /api/datasets/source-consensus?limit=10&offset=180

Allowed query parameters

q
Case-insensitive text search over the public fields named for this dataset.
state
Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
field
Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
limit / offset
Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.

Reuse and corrections

Keep the boundary attached

CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.

Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.

Read the correction policy